Dr. Reddy's Laboratories Limited EBIT

As of the most recent data (June 2026), DRREDDY.BO shows a EBIT of $35B. That compares with $80B in the prior-year period — down 56.7% year over year. That is below the Healthcare sector average of $130B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, DRREDDY.BO's EBIT is now $35B (was $80B) — a 56.7% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Dr. Reddy's Laboratories Limited is outperforming or lagging.

The Healthcare sector average EBIT is about $130B. Dr. Reddy's Laboratories Limited is at $35B, which is lower that average. That is roughly 74.1% below the sector mean. Use the comparison chart on this page to see how DRREDDY.BO stacks up against individual peers as well.

Tracking DRREDDY.BO's ebit over time shows whether Dr. Reddy's Laboratories Limited is scaling, shrinking, or reshaping that part of the business. The current reading is $35B That compares with $80B in the prior-year period — down 56.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has Dr. Reddy's Laboratories Limited's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $35B) with ownership activity and broader fundamentals.